USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

Market Overview ScreenersIndustriesCompanies Community Investment Grader

US Market Open: Feb 9, 12:19 PM 2012

NYSE 8085.68 2.70 Index Moved Up

NASDAQ 2925.75 9.89 Index Moved Up

and more..

sponsered by

Processing
Collecting necessary data for BVF and ELN...

Asset Comparison and Correlation

View All Portfolios

More Actions
- Select Assests
- Optimize Portfolio
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatilities
- Import Equities
- Search Equities
- Filter Tops

Biovail Corp. Common Stoc and

Elan Corp. plc ADR

Volatility

Matrix

Run Correlation

Diversification

Pay attention

Overlapping area represents amount of risk that can be diversified away by holding Biovail Corp. Common Stoc and Elan Corp. plc ADR in the same portfolio (assuming nothing else is changed)

Optimize

Correlation Coefficient

0.0

Parameters

Time Period	1 Month [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Suggest

0.0

Intraday

One Month

^0.00

0.00%

BVF

NYSE

Biovail Corporation Common Sto

Healthcare Sector Shows Uptrend; Valeant Raises Price to Acquire ISTA ? (VRX ...

Galaxy Stocks - Jan 18, 2012

Valeant Pharmaceuticals International, Inc. raised bidding price from $6.50 to $7.50 per share in cash relevant to its earlier proposed price for the acquisition of ISTA Pharmaceuticals.

2012-01-18

Valeant Pharmaceuticals International, Inc. And GlaxoSmithKline plc Announces U.S. FDA Approval For Potiga

Reuters Key Development - Jun 13, 2011

2011-06-13

Valeant Pharmaceuticals Intl Inc Agrees To Acquire Sanitas Group For Approximately EUR314 Million

Reuters Key Development - May 24, 2011

2011-05-24

Valeant Pharmaceuticals International, Inc. Raises FY 2011 EPS Guidance

Reuters Key Development - May 9, 2011

2011-05-09

13.11

Intraday

One Month

^(0.33)

2.46%

ELN

NYSE

Elan Corporation plc ADR

P/E	12.34	P/B Ratio	8.39
Open	13.40	Day Low	13.00
Market Cap	7.711B	Volume	2560167
Last Close	13.44	Short Ratio	2.20
Last Traded	2/9/2012	Year High	14.40
Percent Change	2.46%	EBITDA	196.2M
Year Low	6.10	Absolute Change	0.33
Book Value	1.602	EPS	1.089
Day High	13.61	Target Price	14.25
Current EPS	1.089	This Year EPS	1.14
Next Year EPS	0.10	Current PE	12.34
This Year PE	11.79	Next Year PE	134.40

Top 10 Most Profitable Mid Cap Stocks: AGNC, TCP, HTS, MFA, TNH, ARCC, CIM ...

China Analyst - Feb 3, 2012

American Capital Agency Corp. (NASDAQ:AGNC) is the 1st most profitable stock in this segment of the market. Its net profit margin was 81.66% for the last 12 months.

2012-02-03

More Losers than Gainers in Drug Delivery Industry ? (ALKS, ELN, CBRX, VRX)

Galaxy Stocks - Jan 30, 2012

Alkermes Plc remained in negative territory for the whole trading session even after winning an approval from FDA on third attempt and also released schedule for an upcoming earnings for Q3 of fiscal 2012 on Thursday, Feb. 2, 2012.

2012-01-30

Forbes Earnings Preview: Biogen Idec

Forbes - Jan 26, 2012

By Narrative Science The consensus estimate is $1.47 per share, up 4.3% from a year ago when Biogen Idec reported earnings of $1.41 per share.

2012-01-26

Top 10 Rebounding Biotech Stocks: IDIX, MDVN, PCYC, REGN, JAZZ, GENE, ELN ...

China Analyst - Jan 24, 2012

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) is the 1st best rebounding stock in this segment of the market. It has risen 417% from its 52-week low.

2012-01-24

The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company

2012-02-06

Revenues Skyrocket at Merged Alkermes

2012-02-03

New Study for Alkermes' Vivitrol

2012-02-01